Clinical Trials Logo

Filter by:
NCT ID: NCT02597049 Completed - Clinical trials for Type 2 Diabetes Mellitus

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus

AWARD-10
Start date: November 2015
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the efficacy and safety of the study drug known as dulaglutide when added to sodium-glucose co-transporter 2 (SGLT2) inhibitors in participants with type 2 diabetes mellitus.

NCT ID: NCT02596295 Completed - Clinical trials for Breast Milk Collection

Human Milk Sample Composition in Israeli Mothers and Correlation With Their Diet

Start date: October 2015
Phase: N/A
Study type: Observational

The study will collect human milk from 100 mother of term infants 2-3m after delivery and from 50 mothers of preterm infants 14 and 30 days after delivery. Sample content will be analysed and statistical analysis will look at correlation between demographics, dietary habits and milk composition.

NCT ID: NCT02595398 Completed - Uveitis Clinical Trials

Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis

PEACHTREE
Start date: November 17, 2015
Phase: Phase 3
Study type: Interventional

The study is designed to evaluate the safety and efficacy of suprachoroidally administered triamcinolone acetonide, CLS-TA, in subjects with macular edema associated with non-infectious uveitis.

NCT ID: NCT02592434 Completed - Clinical trials for Juvenile Idiopathic Arthritis

Efficacy Study Of Tofacitinib In Pediatric JIA Population

Start date: June 10, 2016
Phase: Phase 3
Study type: Interventional

Evaluate efficacy, safety and tolerability of tofacitinib in pediatric JIA patients.

NCT ID: NCT02592382 Completed - Otitis Media Clinical Trials

Nasal Xylitol in the Prevention of Otitis Media

Start date: May 1, 2019
Phase: N/A
Study type: Interventional

Acute otitis media (AOM) is one of the most prevalent and costly illnesses in children throughout the world. AOM can lead to chronic otitis media with effusion (OME) resulting in conductive hearing loss that can cause speech, language, academic, and social developmental delays. Complementary and alternative medicines are being widely used for prevention of AOM. Xylitol is a five carbon polyol (sugar alcohol) produced from natural plants and is used for preventing dental caries and AOM in children. It is commercially available in chewing gums, syrups and toothpastes washes, and other products. Xylitol was shown in several studies to prevent the culture of bacteria in the nasopharynx and oral cavity. It was proven to eliminate the ability of bacteria to attach to the mucosa of the upper respiratory system. It was proven to reduce the ability of bacteria to attach to the mucosa of the upper respiratory system. Previous study had shown that oral usage of Xylitol (as chewing gum or syrup) can reduce the incidence of rAOM by 30% as compared to placebo. But this treatment did not gain popularity since the initial clinical trial 30 years. There are several potential reasons for that. First, Xylitol should be administrated 5 times daily in order to be effective. Study that checked usage of oral Xylitol 3 times daily in children with rAOM did not find additional advantage as compared to placebo. Secondly, by using Xylitol orally we rely on the gut absorption and systemic distribution. Xylitol absorbs poorly in the gut and can cause some GI symptoms (like nausea and diarrhea) especially when used in a syrup (the preferred way in small children). In this study the investigators aim to test the yield of Xylitol nasal spray as a preventive treatment in children with rAOM. By using Xylitol as nasal spray we deliver the active compound directly to the action site (nasopharynx- the AOM reservoir) and avoid the GI side effects

NCT ID: NCT02592369 Completed - Clinical trials for Aortic Valve Stenosis

CoreValve™ Evolut R™ FORWARD Study

FORWARD
Start date: January 2016
Phase:
Study type: Observational

Prospective, single arm, multi-center, observational, post market study to document the clinical and device performance outcomes of the Evolut R system used in routine hospital practice in a large patient cohort for the treatment of symptomatic native aortic valve stenosis or a stenosed, insufficient, or combined surgical bioprosthetic valve failure necessitating valve replacement.

NCT ID: NCT02591485 Completed - PTSD Clinical Trials

Prevention of Post Traumatic Stress Disorder Following Trauma by Attention Control Training

Start date: February 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to explore the efficacy of Attention Control Training in preventing the development of Post Traumatic Stress Disorder (PTSD), during the period near after a traumatic event and before PTSD is develop. Individuals who underwent a traumatic event in the past two weeks will be randomly assigned to either Attention Control Training (ACT), designed to normalize threat-related attention biases or a control conditions: without intervention at all. Outcome measures will be a diagnosed of PTSD and the level of severity of symptoms derived from the Clinician Administered PTSD Scale (CAPS-5), after 3 month since the traumatic event had occurred. The investigators expected to find lower ratios of PTSD symptoms in the ACT condition relative to the control condition in which no symptomatic relief is expected.

NCT ID: NCT02590770 Completed - Phobia, Social Clinical Trials

Gaze Contingent Feedback in Social Anxiety Disorder

Start date: October 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether giving gaze-contingent feedback is an effective attention modification procedure, helping in the treatment of social anxiety disorder (SAD)

NCT ID: NCT02586155 Completed - Clinical trials for Coronary Artery Disease

Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD

BETonMACE
Start date: November 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether bromodomain extraterminal domain (BET) inhibition treatment with RVX000222 in high-risk type 2 diabetes mellitus patients with coronary artery disease increases the time to major adverse cardiovascular events.

NCT ID: NCT02585960 Completed - Hemophilia A Clinical Trials

BAX 855 PK-guided Dosing

PROPEL
Start date: November 23, 2015
Phase: Phase 3
Study type: Interventional

1. To compare the efficacy and safety of pharmacokinetic (PK)-guided treatment with BAX 855 targeting FVIII trough levels of 1-3% and approximately 10% (8-12%) 2. To further characterize pharmacokinetic (PK) and pharmacodynamic (PD) parameters of BAX 855